Life Sciences
Top stories summarized by our editors
6/22/2017

Biotech canola and biotech cotton lead to heightened productivity and efficiency gains, earning farmers in Australia income benefits of $1 billion over the past 20 years. "When farmers are given access and the opportunity of growing [biotech] crops, they can grow more on less land, increase crop yields, contribute to international competitiveness and reduce agriculture's environmental impact," said CropLife Australia CEO Matthew Cossey.

More Summaries:
Australia, CropLife Australia
6/22/2017

Twelve bioenergy and biofuel projects are among the recipients of 263 projects awarded $116 million in grants from the Department of Energy. Several of the biofuel projects include the development or manufacturing of nanocellulose.

More Summaries:
DOE, Department of Energy
6/22/2017

Interpace Diagnostics has obtained $12.2 million in net proceeds from its public offering of 9.9 million shares of common stock, common warrants to buy 12.5 million shares and prefunded warrants to buy 2.6 million shares. The net proceeds will be used as working capital, as well as for general corporate functions, payment of legacy contract sales organization obligations and trade payables.

More Summaries:
Interpace Diagnostics
6/22/2017

Philips has agreed to pay $36.7 million for Oregon-based medical device firm Electrical Geodesics in a deal that represents a 36% premium over Electrical's closing share price Wednesday. The acquisition, through which Philips will create an integrated neurological imaging, mapping and therapy guidance portfolio, is expected be completed in the third quarter, pending approval from Electrical's stockholders and the satisfaction of other customary closing conditions.

Full Story:
Fox Business, Reuters
6/22/2017

A round of Series A financing has pulled in an additional $2.1 million for Durham, N.C.-based 410 Medical, raising the round's total proceeds to $5.3 million. The money will be used for the commercialization of the company's LifeFlow Rapid Infuser, which is intended for the delivery of crystalloid fluid for frontline treatment of patients with shock, sepsis or other emergency conditions.

More Summaries:
Series A
6/22/2017

Adaptive Biotechnologies and Johnson & Johnson subsidiary Janssen have agreed on a collaboration to assess the effectiveness of Janssen's Darzalex for multiple myeloma through minimal residual disease measurement using Adaptive's NGS-based ClonoSeq assay. Janssen will provide Adaptive development with funding and potential future milestone payments, as well as an upfront technology access payment of an undisclosed amount.

6/22/2017

SpineGuard and XinRong Medical Group have reached an agreement for the exclusive distribution of SpineGuard's PediGuard in China, Macau and Hong Kong. PediGuard probes provide spine surgeons with real-time alerts for possible vertebral cortical wall breaches using dynamic surgical guidance technology.

Full Story:
Becker's Spine Review
6/22/2017

A 53-patient study showed that the use of Glaukos' iStent device in combination with topical travoprost for treating patients with open-angle glaucoma led to a 35% mean reduction in intraocular pressure at 18 months without device-related adverse events. After a year, the combined treatment demonstrated intraocular pressure of less than or equal to 18 mm Hg in 100% of eyes and intraocular pressure of less than or equal to 15 mm Hg in 87% of eyes.

6/22/2017

The Vantage Titan/Zen Edition 1.5T has been launched by Toshiba Medical for speeding workflow and reducing patient discomfort during MR scans. The system comes with the Pianissimo Zen Edition software for providing noise reduction, Ultrashort Echo Time for imaging in tissues that disappear too quickly and EasyTech for enabling automatic positioning, among other features.

Full Story:
DOTMed
More Summaries:
Toshiba Medical, EasyTech
6/22/2017

The Max and Minnie Tomerlin Voelcker Fund has provided the University of Texas Health Science Center at San Antonio a total of over $2.3 million for a number of studies focusing on cancer and heart disease. In addition to five individual researchers who received $450,000 each via Young Investigator Awards, the center received $75,000 to study anticancer drugs.